8-K: Vaxart Announces $50 Million At-the-Market Offering

Vaxart, Inc. has entered into an agreement to sell up to $50 million of its common stock through an at-the-market offering.

Summary

• Vaxart, Inc. has entered into an At the Market Offering Agreement (ATM Agreement) with Citizens JMP Securities, LLC and B. Riley Securities, Inc.
• Under the agreement, Vaxart may offer and sell shares of its common stock, with an aggregate offering price of up to $50 million.
• The shares will be sold pursuant to an effective registration statement on Form S-3.
• The Managers may sell the shares through methods permitted by law, including sales on The Nasdaq Capital Market or in privately negotiated transactions with the Company's consent.
• Vaxart is not obligated to make any sales of the shares under the ATM Agreement.
• The ATM Agreement may be terminated by the Company with three business days' notice, by the Managers at their discretion, or as otherwise permitted in the agreement.
• The Managers will receive a placement fee of up to 3% of the gross sale price from each sale of the shares.
• Vaxart will also reimburse the Managers for certain specified expenses.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While the capital raise provides financial flexibility, it also introduces potential dilution for existing shareholders.

Positives

• The ATM offering provides Vaxart with flexibility to raise capital as needed.
• The company is not obligated to sell any shares, allowing it to time sales strategically.
• The agreement includes customary terms and conditions, suggesting a standard arrangement.

Negatives

• The offering could dilute existing shareholders' ownership.
• The company will incur placement fees and expenses related to the offering, reducing the net proceeds.
• There is no guarantee that the company will be able to sell all $50 million of shares.

Risks

• Market conditions may not be favorable for selling shares at desired prices.
• The offering could put downward pressure on the company's stock price.
• The company's stock price may be volatile.

Future Outlook

Vaxart intends to use the net proceeds from the sale of shares for general corporate purposes, as outlined in the prospectus.

Industry Context

At-the-market offerings are a common method for publicly traded companies, particularly in the biotech sector, to raise capital. They provide flexibility and can be less dilutive than traditional underwritten offerings.

Comparison to Industry Standards

• Many biotech companies, such as Novavax and Inovio Pharmaceuticals, have utilized ATM offerings to fund research and development.
• The 3% placement fee is within the typical range for ATM offerings in the biotech industry.
• The $50 million offering size is comparable to other ATM offerings by companies with similar market capitalizations.

Stakeholder Impact

• Shareholders may experience dilution of their ownership.
• The company will have additional capital to fund its operations.
• The offering could affect the company's stock price.

Next Steps

• Vaxart will file a prospectus supplement with the SEC in connection with the offering.
• The company may begin selling shares through the Managers at its discretion.
• The company will disclose the number of shares sold and the net proceeds in its future financial reports.

Key Dates

Keywords

At the Market Offering, Common Stock, Capital Raise, Vaxart, VXRT, Securities, Finance